| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/11/2013 | CA2363705C Devices and methods for pain management |
| 06/11/2013 | CA2267664C Human telomerase reverse transcriptase |
| 06/11/2013 | CA2229307C Circular dna molecule with conditional origin of replication, method for preparing same and use thereof in gene therapy |
| 06/09/2013 | CA2798549A1 Novel combination of 4-{3-¬cis-hexahydrocyclopenta¬c|pyrrol-2(1h)-yl|propoxy}benzamide and an nmda receptor antagonist and the pharmacutical compounds containing same |
| 06/07/2013 | CA2761212A1 Disintegrant-free delayed release doxylamine and pyridoxine formulation and process of it manufacturing |
| 06/06/2013 | WO2013082573A1 Acamprosate formulations, methods of using the same, and combinations comprising the same |
| 06/06/2013 | WO2013082565A1 Therapies for disorders of the cornea and conjunctiva |
| 06/06/2013 | WO2013082562A1 Prebiotic formulations and methods of use |
| 06/06/2013 | WO2013082559A1 Methods for treating hyperbilirubinemia with stannsoporfin |
| 06/06/2013 | WO2013082551A1 Induced exon inclusion in spinal muscle atrophy |
| 06/06/2013 | WO2013082548A1 Oligonucleotides for treating expanded repeat diseases |
| 06/06/2013 | WO2013082541A1 Method of preventing acute graft-versus-host disease using oral beclomethasone dipropionate |
| 06/06/2013 | WO2013082540A1 Compositions and methods of treating a proliferative disease with a quinazolinone derivative |
| 06/06/2013 | WO2013082511A1 Methods for overcoming tumor resistance to vegf antagonists |
| 06/06/2013 | WO2013082508A1 Compositions and methods for the treatment and analysis of neurological disorders |
| 06/06/2013 | WO2013082504A1 Bioavailability enhancement delivery composition |
| 06/06/2013 | WO2013082503A1 Peptide particle formulation |
| 06/06/2013 | WO2013082499A1 Targeting micrornas mir-409-5p, mir-379 and mir-154* to treat prostate cancer bone metastasis and drug resistant lung cancer |
| 06/06/2013 | WO2013082490A1 Substituted anilines as ccr(4) antagonists |
| 06/06/2013 | WO2013082469A2 Methods and compositions for treating infections |
| 06/06/2013 | WO2013082462A1 Amorphous ezatiostat ansolvate |
| 06/06/2013 | WO2013082458A1 Reperfusion protection solution and uses thereof |
| 06/06/2013 | WO2013082449A2 Treatment of b cell lymphomas |
| 06/06/2013 | WO2013082429A1 Substituted benzimidazoles and benzopyrazoles as ccr(4) antagonists |
| 06/06/2013 | WO2013082418A1 Microneedle device having a peptide therapeutic agent and an amino acid, methods of making and using the same |
| 06/06/2013 | WO2013082388A1 Peptide deformylase inhibitors |
| 06/06/2013 | WO2013082373A1 Long-acting injectable moxidectin formulations and novel moxidectin crystal forms |
| 06/06/2013 | WO2013082345A1 Aryl dihydropyridinone and piperidinone as mgat2 inhibitors |
| 06/06/2013 | WO2013082344A1 Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use |
| 06/06/2013 | WO2013082338A1 Homomultivalent and heteromultivalent inhibitors of prostate specific membrane antigen (pmsa) and uses thereof |
| 06/06/2013 | WO2013082324A1 Improved modulators of hec1 activity and methods therefor |
| 06/06/2013 | WO2013082286A1 Peptide-mediated delivery of active agents across the blood-brain barrier |
| 06/06/2013 | WO2013082275A1 Inhibitors of phosphodiesterases 11 (pde11) and methods of use to elevate cortisol production |
| 06/06/2013 | WO2013082253A2 Non-hormonal steroid modulators of nf-kb for treatment of disease |
| 06/06/2013 | WO2013082241A2 Improved methods of treating ischemia |
| 06/06/2013 | WO2013082210A1 Anticoagulant reversal agents |
| 06/06/2013 | WO2013082150A1 Small molecule inhibitors of nicotinamide phosphoribosyltransferase (nampt) |
| 06/06/2013 | WO2013082103A1 Caustic agricultural compositions |
| 06/06/2013 | WO2013082102A1 Substituted 4 - phenyl - pyridines for the treatment of nk-1 receptor related diseases |
| 06/06/2013 | WO2013082071A1 Trimethylamine-containing compounds for diagnosis and prediction of disease |
| 06/06/2013 | WO2013082065A1 Zero calorie polyphenol aqueous dispersions |
| 06/06/2013 | WO2013082003A1 Compositions and methods for treating hepatitis c virus |
| 06/06/2013 | WO2013082000A1 Opsin-binding ligands, compositions and methods of use |
| 06/06/2013 | WO2013081981A1 Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for retinal neuroprotection |
| 06/06/2013 | WO2013081783A1 N- (4 -quinolinylmethyl) sulfonamide derivatives and their use as anthelmintics |
| 06/06/2013 | WO2013081722A1 Ploy-hapten with topical hormone alopecia hair regrowth system |
| 06/06/2013 | WO2013081614A1 Hydroxypolyamine salts |
| 06/06/2013 | WO2013081567A1 Effervescent antipsychotic formulations |
| 06/06/2013 | WO2013081566A1 A formulation comprising benzimidazole |
| 06/06/2013 | WO2013081565A1 Pharmaceutical compositions comprising roflumilast and terbutaline |
| 06/06/2013 | WO2013081562A1 Oral formulations comprising ebastine |
| 06/06/2013 | WO2013081462A1 Phytostanols for the prevention or treatment of hepatic inflammation |
| 06/06/2013 | WO2013081452A1 Phosphatidylinositol |
| 06/06/2013 | WO2013081420A2 Phenoxypropanol derivative and pharmaceutical composition containing same |
| 06/06/2013 | WO2013081419A1 Pharmaceutical composition for prevention or treatment of cognitive function disorders comprising spinosyn |
| 06/06/2013 | WO2013081400A2 Novel benzamide derivative and use thereof |
| 06/06/2013 | WO2013081374A1 Pharmaceutical composition for inhibiting angiogenesis containing plant-derived natural compound |
| 06/06/2013 | WO2013081373A1 Pharmaceutical composition for preventing or treating hypertriglyceridemia or hypertriglyceridemia-associated diseases |
| 06/06/2013 | WO2013081372A1 Pharmaceutical composition for preventing or treating hyperlipidemia |
| 06/06/2013 | WO2013081331A1 Skin preparation composition for external use having excellent antiseptic ability |
| 06/06/2013 | WO2013081284A1 Complex antibacterial composition for animals |
| 06/06/2013 | WO2013081177A1 Dry coated tablet |
| 06/06/2013 | WO2013081154A1 Agent for reducing adverse side effects of kinase inhibitor |
| 06/06/2013 | WO2013081147A1 Whitening cosmetic |
| 06/06/2013 | WO2013081146A1 Anti-wrinkle cosmetic |
| 06/06/2013 | WO2013081118A1 Compound having read-through activity |
| 06/06/2013 | WO2013081102A1 Ropinirole-containing adhesive patch |
| 06/06/2013 | WO2013081094A1 Imidazo[1,2-a]pyridine derivative and use thereof for medical purposes |
| 06/06/2013 | WO2013081087A1 Method for preparing optically active compound |
| 06/06/2013 | WO2013081046A1 Extract derived from grape rachis |
| 06/06/2013 | WO2013081044A1 Tablet containing 1-cyclopropyl-8-(difluoromethoxy)-7-[(1r)-1-methyl-2, 3-dihydro-1h-isoindole-5-yl]-4-oxo-1, 4-dihydroquinoline-3-carboxylic acid methanesulfonic acid hydrate |
| 06/06/2013 | WO2013081016A1 Purinone derivative hydrochloride |
| 06/06/2013 | WO2013081014A1 Adhesive skin patch |
| 06/06/2013 | WO2013080999A1 Agent for inhibiting expression of npc1l1 and/or lipg mrna and agent for preventing and/or treating obesity |
| 06/06/2013 | WO2013080271A1 Analgesic |
| 06/06/2013 | WO2013080265A1 Stabilization of s-adenosylmethionine with acid sodium metaphosphate |
| 06/06/2013 | WO2013080222A1 Substituted pyridine derivatives as fabi inhibitors |
| 06/06/2013 | WO2013080208A1 Methods for providing a personalised list of dietary nutrients and supplements |
| 06/06/2013 | WO2013080156A1 3,7-disubstituted octahydro-2h-pyrido[4,3-e][1,3]oxazin-2-one antibiotics |
| 06/06/2013 | WO2013080148A1 A process for the preparation of solid dispersion of lopinavir and ritonavir |
| 06/06/2013 | WO2013080141A1 Pyrazolopyrrolidine compounds |
| 06/06/2013 | WO2013080120A1 Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease |
| 06/06/2013 | WO2013080046A1 Lurasidone novel dosage regimens and use thereof for the treatment, prevention, and/or management of at least one cns disorder |
| 06/06/2013 | WO2013080036A1 Azetidine-substituted quinoxaline-type piperidine compounds and uses thereof |
| 06/06/2013 | WO2013080028A1 Composition based on ubidecarenone |
| 06/06/2013 | WO2013079992A1 Reuterin-producing lactobacillus brevis |
| 06/06/2013 | WO2013079964A1 Combination treatment of cancer |
| 06/06/2013 | WO2013079957A1 Antimicrobial animal product |
| 06/06/2013 | WO2013079889A1 Method for simultaneously substituting and cross-linking a polysaccharide by means of the hydroxyl functions thereof |
| 06/06/2013 | WO2013079873A1 Phacetoperane for the treatment of attention-deficit hyperactivity disorder |
| 06/06/2013 | WO2013079754A1 Fluorinated indolenines for use in the treatment of cancer |
| 06/06/2013 | WO2013079745A1 Compounds that inhibit aggregation of the beta amyloid peptide |
| 06/06/2013 | WO2013079741A1 Pharmaceutical composition for the treatment of cerebrovascular diseases |
| 06/06/2013 | WO2013079696A1 Methods of treatment and prevention of eye diseases |
| 06/06/2013 | WO2013079687A1 Inkt cell modulators and methods of using the same |
| 06/06/2013 | WO2013079668A1 Piperidine derivatives, pharmaceutical compositions and uses thereof |
| 06/06/2013 | WO2013079624A1 Composition comprising vicenin-2 having a beneficial effect on neurological and/or cognitive function |
| 06/06/2013 | WO2013079623A1 Vicenin 2 and analogues thereof for use as an antispasmodic and/or prokinetic agent |
| 06/06/2013 | WO2013079589A1 Novel crystalline form of ticagrelor and process for the preparation thereof |
| 06/06/2013 | WO2013079586A1 Carboxamide-substituted heteroaryl-pyrazoles and the use thereof |